Loading…
The History and Future of Probenecid
Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, through...
Saved in:
Published in: | Cardiovascular toxicology 2012-03, Vol.12 (1), p.1-9 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223 |
---|---|
cites | cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223 |
container_end_page | 9 |
container_issue | 1 |
container_start_page | 1 |
container_title | Cardiovascular toxicology |
container_volume | 12 |
creator | Robbins, Nathan Koch, Sheryl E. Tranter, Michael Rubinstein, Jack |
description | Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses. |
doi_str_mv | 10.1007/s12012-011-9145-8 |
format | article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_926885763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A711762786</galeid><sourcerecordid>A711762786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</originalsourceid><addsrcrecordid>eNp1kUFPFTEUhRujAQR-ABsyURNXg_fembbTJSEiJiS6wHXTae_AkPem0M4s-Pf0-VDUSLpo037n3NMcIY4QThBAf8pIgFQDYm2wlXX3SuyhlKYGkub15txArQ3IXfE251sAIlJyR-wSmqZrTbMnPlzdcHUx5jmmh8pNoTpf5iVxFYfqe4o9T-zHcCDeDG6V-fBp3xc_zj9fnV3Ul9--fD07vax9a_RcY4DeaxWAjdMKeiQpAyLr3hBpLY3RrWLP3jTKa2oocHDkGvBDq0q0Zl983PrepXi_cJ7tesyeVys3cVyyNaS6TmrVFPLdP-RtXNJUwlmDXSGgUwV6_xJEykjdaaA_qGu3YjtOQ5yT85vB9lQjakX6p9fJf6iyAq9HHycexnL_lwC3Ap9izokHe5fGtUsPFsFu2rPb9mxpz27as13RHD8FXvo1h9-KX3UVgLZALk_TNafnH73s-ggJPp7f</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2695787026</pqid></control><display><type>article</type><title>The History and Future of Probenecid</title><source>Springer Link</source><creator>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</creator><creatorcontrib>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</creatorcontrib><description>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</description><identifier>ISSN: 1530-7905</identifier><identifier>EISSN: 1559-0259</identifier><identifier>DOI: 10.1007/s12012-011-9145-8</identifier><identifier>PMID: 21938493</identifier><language>eng</language><publisher>New York: Humana Press Inc</publisher><subject>Animals ; Anti-Bacterial Agents - antagonists & inhibitors ; Anti-Bacterial Agents - pharmacokinetics ; Antibiotics ; Biomedical and Life Sciences ; Biomedicine ; Calcium ; Cardiology ; Cidofovir ; Depression ; Depression - drug therapy ; Depression - metabolism ; Emtricitabine ; Excretion ; Fura-2 ; Fura-2 - metabolism ; Gout ; Gout - drug therapy ; Gout - metabolism ; Health services ; Humans ; Hydrochlorothiazide ; Kidney ; Leakage ; Medical colleges ; Neurology ; Penicillin ; Pharmacology/Toxicology ; Physiological aspects ; Probenecid ; Probenecid - chemistry ; Probenecid - pharmacokinetics ; Probenecid - therapeutic use ; Renal function ; Reviews ; Transient receptor potential proteins ; TRPV Cation Channels - physiology ; Uricosuric Agents - chemistry ; Uricosuric Agents - pharmacokinetics ; Uricosuric Agents - therapeutic use</subject><ispartof>Cardiovascular toxicology, 2012-03, Vol.12 (1), p.1-9</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Springer Science+Business Media, LLC 2011.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</citedby><cites>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21938493$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robbins, Nathan</creatorcontrib><creatorcontrib>Koch, Sheryl E.</creatorcontrib><creatorcontrib>Tranter, Michael</creatorcontrib><creatorcontrib>Rubinstein, Jack</creatorcontrib><title>The History and Future of Probenecid</title><title>Cardiovascular toxicology</title><addtitle>Cardiovasc Toxicol</addtitle><addtitle>Cardiovasc Toxicol</addtitle><description>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - antagonists & inhibitors</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Antibiotics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Calcium</subject><subject>Cardiology</subject><subject>Cidofovir</subject><subject>Depression</subject><subject>Depression - drug therapy</subject><subject>Depression - metabolism</subject><subject>Emtricitabine</subject><subject>Excretion</subject><subject>Fura-2</subject><subject>Fura-2 - metabolism</subject><subject>Gout</subject><subject>Gout - drug therapy</subject><subject>Gout - metabolism</subject><subject>Health services</subject><subject>Humans</subject><subject>Hydrochlorothiazide</subject><subject>Kidney</subject><subject>Leakage</subject><subject>Medical colleges</subject><subject>Neurology</subject><subject>Penicillin</subject><subject>Pharmacology/Toxicology</subject><subject>Physiological aspects</subject><subject>Probenecid</subject><subject>Probenecid - chemistry</subject><subject>Probenecid - pharmacokinetics</subject><subject>Probenecid - therapeutic use</subject><subject>Renal function</subject><subject>Reviews</subject><subject>Transient receptor potential proteins</subject><subject>TRPV Cation Channels - physiology</subject><subject>Uricosuric Agents - chemistry</subject><subject>Uricosuric Agents - pharmacokinetics</subject><subject>Uricosuric Agents - therapeutic use</subject><issn>1530-7905</issn><issn>1559-0259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kUFPFTEUhRujAQR-ABsyURNXg_fembbTJSEiJiS6wHXTae_AkPem0M4s-Pf0-VDUSLpo037n3NMcIY4QThBAf8pIgFQDYm2wlXX3SuyhlKYGkub15txArQ3IXfE251sAIlJyR-wSmqZrTbMnPlzdcHUx5jmmh8pNoTpf5iVxFYfqe4o9T-zHcCDeDG6V-fBp3xc_zj9fnV3Ul9--fD07vax9a_RcY4DeaxWAjdMKeiQpAyLr3hBpLY3RrWLP3jTKa2oocHDkGvBDq0q0Zl983PrepXi_cJ7tesyeVys3cVyyNaS6TmrVFPLdP-RtXNJUwlmDXSGgUwV6_xJEykjdaaA_qGu3YjtOQ5yT85vB9lQjakX6p9fJf6iyAq9HHycexnL_lwC3Ap9izokHe5fGtUsPFsFu2rPb9mxpz27as13RHD8FXvo1h9-KX3UVgLZALk_TNafnH73s-ggJPp7f</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Robbins, Nathan</creator><creator>Koch, Sheryl E.</creator><creator>Tranter, Michael</creator><creator>Rubinstein, Jack</creator><general>Humana Press Inc</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20120301</creationdate><title>The History and Future of Probenecid</title><author>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - antagonists & inhibitors</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Antibiotics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Calcium</topic><topic>Cardiology</topic><topic>Cidofovir</topic><topic>Depression</topic><topic>Depression - drug therapy</topic><topic>Depression - metabolism</topic><topic>Emtricitabine</topic><topic>Excretion</topic><topic>Fura-2</topic><topic>Fura-2 - metabolism</topic><topic>Gout</topic><topic>Gout - drug therapy</topic><topic>Gout - metabolism</topic><topic>Health services</topic><topic>Humans</topic><topic>Hydrochlorothiazide</topic><topic>Kidney</topic><topic>Leakage</topic><topic>Medical colleges</topic><topic>Neurology</topic><topic>Penicillin</topic><topic>Pharmacology/Toxicology</topic><topic>Physiological aspects</topic><topic>Probenecid</topic><topic>Probenecid - chemistry</topic><topic>Probenecid - pharmacokinetics</topic><topic>Probenecid - therapeutic use</topic><topic>Renal function</topic><topic>Reviews</topic><topic>Transient receptor potential proteins</topic><topic>TRPV Cation Channels - physiology</topic><topic>Uricosuric Agents - chemistry</topic><topic>Uricosuric Agents - pharmacokinetics</topic><topic>Uricosuric Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robbins, Nathan</creatorcontrib><creatorcontrib>Koch, Sheryl E.</creatorcontrib><creatorcontrib>Tranter, Michael</creatorcontrib><creatorcontrib>Rubinstein, Jack</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cardiovascular toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robbins, Nathan</au><au>Koch, Sheryl E.</au><au>Tranter, Michael</au><au>Rubinstein, Jack</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The History and Future of Probenecid</atitle><jtitle>Cardiovascular toxicology</jtitle><stitle>Cardiovasc Toxicol</stitle><addtitle>Cardiovasc Toxicol</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>12</volume><issue>1</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1530-7905</issn><eissn>1559-0259</eissn><abstract>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</abstract><cop>New York</cop><pub>Humana Press Inc</pub><pmid>21938493</pmid><doi>10.1007/s12012-011-9145-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1530-7905 |
ispartof | Cardiovascular toxicology, 2012-03, Vol.12 (1), p.1-9 |
issn | 1530-7905 1559-0259 |
language | eng |
recordid | cdi_proquest_miscellaneous_926885763 |
source | Springer Link |
subjects | Animals Anti-Bacterial Agents - antagonists & inhibitors Anti-Bacterial Agents - pharmacokinetics Antibiotics Biomedical and Life Sciences Biomedicine Calcium Cardiology Cidofovir Depression Depression - drug therapy Depression - metabolism Emtricitabine Excretion Fura-2 Fura-2 - metabolism Gout Gout - drug therapy Gout - metabolism Health services Humans Hydrochlorothiazide Kidney Leakage Medical colleges Neurology Penicillin Pharmacology/Toxicology Physiological aspects Probenecid Probenecid - chemistry Probenecid - pharmacokinetics Probenecid - therapeutic use Renal function Reviews Transient receptor potential proteins TRPV Cation Channels - physiology Uricosuric Agents - chemistry Uricosuric Agents - pharmacokinetics Uricosuric Agents - therapeutic use |
title | The History and Future of Probenecid |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A12%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20History%20and%20Future%20of%20Probenecid&rft.jtitle=Cardiovascular%20toxicology&rft.au=Robbins,%20Nathan&rft.date=2012-03-01&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1530-7905&rft.eissn=1559-0259&rft_id=info:doi/10.1007/s12012-011-9145-8&rft_dat=%3Cgale_proqu%3EA711762786%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2695787026&rft_id=info:pmid/21938493&rft_galeid=A711762786&rfr_iscdi=true |